Artificial intelligence and the future of antibody discovery

In partnership with:

Dive into our report and…

• Understand the significance of antibody therapeutics.
• Discover how AI and ML are transforming antibody discovery, for example, by predicting and correcting antibody structures early in development.
• Learn about current challenges with using AI in antibody discovery, such as the need for balanced datasets, and how these can be addressed.
• Gain insight into how in silico and wet lab approaches are being integrated more closely to facilitate R&D, and
• Take a look at what the future holds for AI and human scientists in antibody discovery.

More about this report:

Antibody therapies constitute a vast global market: currently valued at over $250 billion, the market for antibodies is expected to exceed $850 billion worldwide by 2032. Driving forces behind this growth are the high incidence of chronic diseases, cancer, and other conditions, as well as increasing demand for more targeted treatments. 

In this market landscape, AI is establishing itself as a powerful tool with the potential to bring treatments to the bedside sooner and improve patient outcomes. 

Our comprehensive report, sponsored by Benchling, delves into how AI is fuelling innovation in antibody discovery today, and how the technology will continue to impact the field in the future.